VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 5, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to report that following the resumption of the clinical development of TectinTM, the Company had a pre-CTA (Clinical Trial Applications) meeting with Health Canada last Thursday. The meeting discussed and agreed upon the study methodology of the new randomized, double-blind controlled study (TEC-006) in patients with inadequately controlled moderate to severe cancer related pain. The design of the new trial will be much simpler than that of WEX-014, which will minimize patient's burden and thereby accelerate the patient recruitment. Also, the number of subjects required to complete the study will be substantially reduced.
